Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Shareholder Meeting (August 2025)
13 slides from Little Green Pharma's shareholder meeting presentation, August 2025
Slide 1: 2025 AGM presentation
2025 AGM presentation ASX:LGP August 2025 The most trusted medicinal cannabis brand
Slide 2: Disclaimer
Disclaimer Disclaimer Not financial product advice This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) and its This document does not constitute financial product advice or take into account your investment objectives, taxation activities current as
Slide 3: Little Green Pharma
ABOUT LGP Little Green Pharma 30t 5 BRANDS 31 PRODUCTS 4 FACILITIES PRODUCTION CAPACITY AUSTRALIAN 11 94 STAFF ACROSS 20+ STRAINS DISTRIBUTION BUSINESS DISTRIBUTION TERRITORIES 5 COUNTRIES GENETICS BANK 4
Slide 4: 2025 highlights
2025 HIGHLIGHTS 2025 highlights • Strong financial results, with revenue up 43% to $36.8 million, a net profit after tax of $3.3 million, and Adjusted EBITDA of $2.9 million • German market surging, with LGP Danish facility 2 hours from border and shutdown of key Portuguese competitors processing im
Slide 5: Finance highlights
FINANCE HIGHLIGHTS Finance highlights • Revenue CAGR: 52% over FY2022–FY2025 with record revenue of $36.8 million in FY2025, up 43% on FY2024 • Adjusted EBITDA: $2.9 million (up from negative $1.6m in FY2024) • Net profit after tax (NPAT): $3.3 million (vs FY2024 loss of $8.2m) • Net Tangible Assets
Slide 6: Global assets
GLOBAL ASSETS Global assets Denmark: largest production facility in Europe 2 hours from German border, with new 2tpa room commissioned during year and poised to take advance of expanded Danish cannabis cultivation and import rules Western Australia: Subcontracted indoor facility transitioned to Craf
Slide 7: Market update
MARKET UPDATE Market update Australia • Australia continues to be a fast-growing cannabis market with significant competition and pricing pressure from imported products • Recent media reporting on over-prescribing has prompted TGA-led regulatory reviews into suitability of non-approved product path
Slide 8: Market update
MARKET UPDATE Market update Germany • Legalisation has driven ~81 tonnes of imports in first two quarters of CY2025, up from ~72 tonnes across all of CY24 • Strong demand for LGP products continue with POs through to end June 2026 • New German governing coalition has retained adult use legislation,
Slide 9: ASX listed peer comparison
PEER COMPARISON ASX listed peer comparison Graph shows share price comparison between LGP and various listed peers (ECS, AGH, CAN, VIT, BXN, BOT) since Jan 2025 (as at 18 August 2025) • Excellent share price performance compared to listed peers during a challenging market environment 9
Slide 10: North American stocks comparison
PEER COMPARISON North American stocks comparison Graph shows share price comparison between LGP and with two key North American cannabis ETFs (as at 19 August 2025) • Recent jump in North American interest reflecting likelihood of US down-scheduling in near term, with potential re-rating of Australi
Slide 11: Corporate overview
CORPORATE OVERVIEW Corporate overview Capital structure Shareholder structure Current share price1 $0.115 Shares outstanding1 ~304 million Options and performance rights on Issue2 ~24 million 24% Market capitalisation (undiluted) ~$35 million 37% Cash reserves (30 June 2025) ~$2.5 million Long term
Slide 12: Value proposition
VALUE PROPOSITION Value proposition LGP extremely well positioned to capitalise on consolidation opportunities and potential market re-rating over next 12 months: • A leading cannabis company in both Australia and Europe • Positioned in rapid growth markets and owner of largest cannabis facility in
Slide 13: Q&A
Q&A
Little Green Pharma — Shareholder Meeting (August 2025) on 6ix